• LIST OF FIGURES
  • SUMMARY
  • 1. INTRODUCTION
  • 2. PROBLEMS INVOLVED IN DEVELOPING DRUGS
  • 2.1 DRUG INNOVATION AS AN INVESTMENT UNDER UNCERTAINTY
  • 2.2 THE ROLE OF PATENTS
  • 3. ON THE OPTIMAL DRUG PRICING
  • 3.1 MONOPOLY DRUG PRICING DURING PATENT PROTECTION
  • 3.2 DRUG PRICING UNDER COMPETITION (WITHOUT PATENT)
  • 4. EXPERIENCES OF REFERENCE PRICES IN THE GERMAN DRUG MARKET
  • 4.1 INTRODUCING REFERENCE PRICE SYSTEM IN 1989
  • 5.2 THE EFFECTS OF REFERENCE PRICES FOR THE GERMAN DRUG MARKET
  • 5. CONCLUDING REMARKS
  • 5.1 MAIN FINDINGS
  • 5.2 ON THE PRICING METHOD SUGGESTED BY CIPE
  • REFERENCES